Glesatinib - Moligand™, ≥98% , Tyrosine-protein kinase TIE-2 inhibitor, CAS No.936694-12-1, Tyrosine-protein kinase TIE-2 inhibitor

CAS: 936694-12-1 Cat. No.: G610571 Summenformel: C₃₁H₂₇F₂N₅O₃S₂ Molekulargewicht: 619.70

GRADE & PURITY Moligand™, ≥98%

Synonyms

YRCHYHRCBXNYNU-UHFFFAOYSA-N | Adenosine 3,5'-cyclic monophosphoric acid | MG90265gly | D11136 | GTPL9133 | AKOS040741789 | N-(3-fluoro-4-(2-(5-((2-methoxyethylamino)methyl)pyridin-2-yl)thieno[3,2-b]pyridin-7-yloxy)phenylcarbamothioyl)-2-(4-fluorophenyl)ac

Storage

Store at -20°C

Shipped In

Ice chest + Ice pads

Übersicht

Glesatinib (MGCD265) is a potent MET/SMO dual inhibitor. Glesatinib, a tyrosine kinase inhibitor, antagonizes P-glycoprotein (P-gp) mediated multidrug resistance (MDR) in non-small cell lung cancer (NSCLC).

Specifications

Synonyme

YRCHYHRCBXNYNU-UHFFFAOYSA-N | Adenosine 3,5'-cyclic monophosphoric acid | MG90265gly | D11136 | GTPL9133 | AKOS040741789 | N-(3-fluoro-4-(2-(5-((2-methoxyethylamino)methyl)pyridin-2-yl)thieno[3,2-b]pyridin-7-yloxy)phenylcarbamothioyl)-2-(4-fluorophenyl)ac

Spezifikationen & Reinheit

Moligand™, ≥98%

Storage

Store at -20°C

Verschickt in

Ice chest + Ice pads

Dieses Produkt erfordert Kühlkettenversand. Grundversand und andere Economy-Optionen sind nicht verfügbar.

Note

Moligand™

Aktionsart

INHIBITOR

Mechanismus der Wirkung

Tyrosine-protein kinase TIE-2 inhibitor

Reinheit

≥98%

Produkteigenschaften

ALogP

5.1

Namen und Kennungen

Kanonisches Lächeln

COCCNCC1=CN=C(C=C1)C2=CC3=NC=CC(=C3S2)OC4=C(C=C(C=C4)NC(=S)NC(=O)CC5=CC=C(C=C5)F)F

IUPAC Name

N-[[3-fluoro-4-[2-[5-[(2-methoxyethylamino)methyl]pyridin-2-yl]thieno[3,2-b]pyridin-7-yl]oxyphenyl]carbamothioyl]-2-(4-fluorophenyl)acetamide

InChIKey

YRCHYHRCBXNYNU-UHFFFAOYSA-N

INCHI

1S/C31H27F2N5O3S2/c1-40-13-12-34-17-20-4-8-24(36-18-20)28-16-25-30(43-28)27(10-11-35-25)41-26-9-7-22(15-23(26)33)37-31(42)38-29(39)14-19-2-5-21(32)6-3-19/h2-11,15-16,18,34H,12-14,17H2,1H3,(H2,37,38,39,42)

Isomere SMILES

COCCNCC1=CN=C(C=C1)C2=CC3=NC=CC(=C3S2)OC4=C(C=C(C=C4)NC(=S)NC(=O)CC5=CC=C(C=C5)F)F

Alternative CAS-Nummer

936694-12-1,1044577-56-1, 2319837-80-2

MeSH-Eintrag

glesatinib

Molekulargewicht

619.70

Taxonomic Classification

Taxonomy Tree

• Kingdom Organic compounds
  • Superclass Benzenoids
    • Klasse Benzene and substituted derivatives
      • Subclass N-phenylthioureas

• Kingdom: Organic compounds
• Superclass: Benzenoids
• Klasse: Benzene and substituted derivatives
• Subclass: N-phenylthioureas
• Intermediate Tree Nodes: Not available
• Direct Parent: N-acyl-phenylthioureas
• Alternative Parents: Diarylethers Phenylacetamides Thienopyridines 2,3,5-trisubstituted thiophenes Phenoxy compounds Phenol ethers Aralkylamines Fluorobenzenes Pyridines and derivatives Aryl fluorides Heteroaromatic compounds Amino acids and derivatives Thioureas Dialkylamines Dialkyl ethers Azacyclic compounds Hydrocarbon derivatives Carbonyl compounds Organic oxides Organofluorides
• Molecular Framework: Aromatic heteropolycyclic compounds
• Substituents: N-acyl-phenylthiourea - Diaryl ether - Phenylacetamide - Thienopyridine - Phenol ether - Phenoxy compound - 2,3,5-trisubstituted thiophene - Fluorobenzene - Halobenzene - Aralkylamine - Aryl halide - Pyridine - Aryl fluoride - Heteroaromatic compound - Thiophene - Thiourea - Amino acid or derivatives - Carboxylic acid derivative - Dialkyl ether - Secondary aliphatic amine - Ether - Azacycle - Organoheterocyclic compound - Secondary amine - Organic oxide - Organic oxygen compound - Hydrocarbon derivative - Organic nitrogen compound - Carbonyl group - Amine - Organohalogen compound - Organofluoride - Organonitrogen compound - Organooxygen compound - Organosulfur compound - Aromatic heteropolycyclic compound
• Beschreibung: This compound belongs to the class of organic compounds known as n-acyl-phenylthioureas. These are thiourea derivatives where one nitrogen atom of the urea group is linked to a phenyl group and the other is acylated.
• External Descriptors: Not available

Data sources

1. Djoumbou Feunang Y, Eisner R, Knox C, Chepelev L, Hastings J, Owen G, Fahy E, Steinbeck C, Subramanian S, Bolton E, Greiner R, and Wishart DS. ClassyFire: Automated Chemical Classification With A Comprehensive, Computable Taxonomy. Journal of Cheminformatics, 2016, 8:61.

DOI: 10.1186/s13321-016-0174-y

Zugehörige Ziele (menschlich)

MET Tclin Hepatocyte growth factor receptor (1 Activities)

Discover Target: MET

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

KDR Tclin Vascular endothelial growth factor receptor 2 (1 Activities)

Discover Target: KDR

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

ABL1 Tclin Tyrosine-protein kinase ABL (18331 Activities)

Discover Target: ABL1

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

EGFR Tclin Epidermal growth factor receptor erbB1 (33727 Activities)

Discover Target: EGFR

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

INSR Tclin Insulin receptor (5558 Activities)

Discover Target: INSR

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

TOP2A Tclin DNA topoisomerase II alpha (6317 Activities)

Discover Target: TOP2A

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

IMPDH2 Tclin Inosine-5'-monophosphate dehydrogenase 2 (1326 Activities)

Discover Target: IMPDH2

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

PDGFRB Tclin Platelet-derived growth factor receptor beta (5195 Activities)

Discover Target: PDGFRB

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

IGF1R Tclin Insulin-like growth factor I receptor (8605 Activities)

Discover Target: IGF1R

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

DCK Tchem Deoxycytidine kinase (530 Activities)

Discover Target: DCK

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

MAPK11 Tchem MAP kinase p38 beta (2785 Activities)

Discover Target: MAPK11

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

LCK Tclin Tyrosine-protein kinase LCK (9212 Activities)

Discover Target: LCK

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

NQO2 Tchem Quinone reductase 2 (885 Activities)

Discover Target: NQO2

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

ADK Tchem Adenosine kinase (1481 Activities)

Discover Target: ADK

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

MAPK14 Tchem MAP kinase p38 alpha (12866 Activities)

Discover Target: MAPK14

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

AK2 Tbio Adenylate kinase 2 (264 Activities)

Discover Target: AK2

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

GSK3B Tclin Glycogen synthase kinase-3 beta (11785 Activities)

Discover Target: GSK3B

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

PRKACB Tchem cAMP-dependent protein kinase beta-1 catalytic subunit (589 Activities)

Discover Target: PRKACB

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

PRKCZ Tchem Protein kinase C zeta (2414 Activities)

Discover Target: PRKCZ

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

MAP2K6 Tchem Dual specificity mitogen-activated protein kinase kinase 6 (1284 Activities)

Discover Target: MAP2K6

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

MYLK Tchem Myosin light chain kinase, smooth muscle (1267 Activities)

Discover Target: MYLK

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

CSNK1G1 Tchem Casein kinase I gamma 1 (2496 Activities)

Discover Target: CSNK1G1

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

FGFR1 Tclin Fibroblast growth factor receptor 1 (9149 Activities)

Discover Target: FGFR1

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

STK3 Tchem Serine/threonine-protein kinase MST2 (3069 Activities)

Discover Target: STK3

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

PRKAG1 Tchem AMP-activated protein kinase, gamma-1 subunit (254 Activities)

Discover Target: PRKAG1

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

CSNK1D Tchem Casein kinase I delta (4546 Activities)

Discover Target: CSNK1D

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

MAP2K5 Tchem Dual specificity mitogen-activated protein kinase kinase 5 (650 Activities)

Discover Target: MAP2K5

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

SRC Tclin Tyrosine-protein kinase SRC (10310 Activities)

Discover Target: SRC

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

MAP2K3 Tchem Dual specificity mitogen-activated protein kinase kinase 3 (632 Activities)

Discover Target: MAP2K3

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

CDK6 Tclin Cyclin-dependent kinase 6 (1724 Activities)

Discover Target: CDK6

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

PRKAG2 Tchem AMP-activated protein kinase, gamma-2 subunit (243 Activities)

Discover Target: PRKAG2

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

AKT2 Tchem Serine/threonine-protein kinase AKT2 (4301 Activities)

Discover Target: AKT2

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

AKT3 Tchem Serine/threonine-protein kinase AKT3 (3157 Activities)

Discover Target: AKT3

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

GRK2 Tchem G-protein coupled receptor kinase 2 (1019 Activities)

Discover Target: GRK2

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

PYGB Tchem Brain glycogen phosphorylase (474 Activities)

Discover Target: PYGB

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

AURKB Tchem Serine/threonine-protein kinase Aurora-B (6805 Activities)

Discover Target: AURKB

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

RPS6KA4 Tchem Ribosomal protein S6 kinase alpha 4 (2104 Activities)

Discover Target: RPS6KA4

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

ROCK1 Tclin Rho-associated protein kinase 1 (4723 Activities)

Discover Target: ROCK1

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

PIM1 Tchem Serine/threonine-protein kinase PIM1 (9629 Activities)

Discover Target: PIM1

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

PKN2 Tchem Protein kinase N2 (1991 Activities)

Discover Target: PKN2

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

CSK Tchem Tyrosine-protein kinase CSK (2395 Activities)

Discover Target: CSK

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

RPS6KA5 Tchem Ribosomal protein S6 kinase alpha 5 (3355 Activities)

Discover Target: RPS6KA5

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

PRKD3 Tchem Protein kinase C nu (2315 Activities)

Discover Target: PRKD3

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

PRKCI Tchem Protein kinase C iota (2821 Activities)

Discover Target: PRKCI

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

SYK Tclin Tyrosine-protein kinase SYK (7372 Activities)

Discover Target: SYK

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

PLK1 Tchem Serine/threonine-protein kinase PLK1 (28605 Activities)

Discover Target: PLK1

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

JAK1 Tclin Tyrosine-protein kinase JAK1 (8569 Activities)

Discover Target: JAK1

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

RPS6KA1 Tchem Ribosomal protein S6 kinase alpha 1 (2796 Activities)

Discover Target: RPS6KA1

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

RPS6KA6 Tchem Ribosomal protein S6 kinase alpha 6 (2027 Activities)

Discover Target: RPS6KA6

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

PFKP Tbio Phosphofructokinase platelet type (224 Activities)

Discover Target: PFKP

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

CSNK1E Tclin Casein kinase I epsilon (1412 Activities)

Discover Target: CSNK1E

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

CAMK4 Tbio CaM kinase IV (2116 Activities)

Discover Target: CAMK4

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

Zugehörige Ziele (nicht menschlich)

Cdk4 Cyclin-dependent kinase 4 (3 Activities)

Discover Target: Cdk4

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

Pygl Liver glycogen phosphorylase (81 Activities)

Discover Target: Pygl

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

Prkcd Protein kinase C delta (192 Activities)

Discover Target: Prkcd

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

Prkcb Protein kinase C beta (2 Activities)

Discover Target: Prkcb

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

Mapk1 MAP kinase ERK2 (650 Activities)

Discover Target: Mapk1

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

Camk2g CaM kinase II gamma (1 Activities)

Discover Target: Camk2g

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

Tec Tyrosine-protein kinase TEC (25 Activities)

Discover Target: Tec

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

AIRC Multifunctional protein ADE2 (8 Activities)

Discover Target: AIRC

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

rep Replicase polyprotein 1ab (378 Activities)

Discover Target: rep

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

Septin9 Septin-9 (1 Activities)

Discover Target: Septin9

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

Acadvl Very long-chain specific acyl-CoA dehydrogenase, mitochondrial (1 Activities)

Discover Target: Acadvl

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

SARS-CoV-2 (38078 Activities)

Explore this target

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

Wirkungsmechanismen

Chemische und physikalische Eigenschaften

• Molekulargewicht: 619.700 g/mol
• XLogP3: 5.100
• Hydrogen Bond Donor Count: 3
• Hydrogen Bond Acceptor Count: 10
• Rotatable Bond Count: 11
• Exact Mass: 619.152 Da
• Monoisotopic Mass: 619.152 Da
• Topological Polar Surface Area: 158.000 Ų
• Heavy Atom Count: 43
• Formal Charge: 0
• Complexity: 901.000
• Isotope Atom Count: 0
• Defined Atom Stereocenter Count: 0
• Undefined Atom Stereocenter Count: 0
• Defined Bond Stereocenter Count: 0
• Undefined Bond Stereocenter Count: 0
• The total count of all stereochemical bonds: 0
• Covalently-Bonded Unit Count: 1

Application Protocols

No vendor-validated application protocols are provided in the Product Data for this item. The following are example, general-purpose procedures commonly used for small-molecule kinase inhibitors; they are not product specifications and should be optimized by the end user.

• Preparation of DMSO stock

• Weigh the required amount quickly in a fume hood.
• Add anhydrous DMSO to achieve a tentative 10–20 mM concentration (adjust based on actual solubility).
• Vortex until fully dissolved; if necessary, brief sonication can help. Filter through PTFE (0.2 µm) if particulates persist.
• Aliquot into amber vials or polypropylene tubes; store at −20°C.

• Biochemical kinase assay (generic setup)

• Prepare serial dilutions in DMSO (e.g., 10-point half-log series).
• Transfer to assay buffer to reach the desired final inhibitor concentrations, keeping DMSO constant across wells (e.g., 0.5–1% v/v).
• Include vehicle controls and a known reference inhibitor for assay QC. Readout by ADP production, fluorescence polarization, or TR-FRET per kit instructions.

• Cell-based assay (generic setup)

• Pre-dilute stock into media to the target concentration; ensure final DMSO ≤0.1–0.5% v/v depending on cell sensitivity.
• Treat cells for an empirically determined period (e.g., 1–4 h for acute pathway modulation). Quantify target phosphorylation by Western blot or phospho-ELISA.

These outlines require adaptation to specific targets, cell lines, assay formats, and instrumentation.

Biological Roles

General/literature context (no medical/clinical claims): • Glesatinib is described in the literature as a small-molecule, ATP-competitive inhibitor with primary activity against the receptor tyrosine kinase MET (HGFR). Reports also describe activity on AXL and related RTKs (e.g., RON/MST1R, and angiogenic kinases) depending on assay format and conditions. Potency and selectivity values are method-dependent; consult primary sources for specific Ki/IC50 data. • Biochemical role: By occupying the ATP-binding cleft, it is used to suppress MET-dependent phosphorylation cascades, enabling dissection of upstream ligand (HGF) stimulation and downstream pathways (e.g., PI3K/AKT, MAPK/ERK) in cellular systems. • Chemical biology use: Serves as a tool compound to benchmark MET-pathway dependency, evaluate synthetic lethality hypotheses, and calibrate phospho-proteomics and target engagement assays (e.g., CETSA, NanoBRET target engagement) under controlled exposure. • ADME/transport considerations (literature): Like many kinase inhibitors, interactions with efflux transporters and plasma protein binding can influence apparent cellular potency; these parameters are assay- and system-specific.

Item-specific biological specifications (tested activities, EC50/IC50, spectrum) are not provided in the Product Data; verify against the current literature and the item’s CoA if included.

Buffer Applications

This compound is not a buffering reagent. It does not establish defined pH ranges or buffering capacity in solution. For experimental use, it is typically dissolved in DMSO and then diluted into preselected assay buffers appropriate for the biological system (e.g., HEPES, PBS, Tris, or proprietary kinase assay buffers). Ensure the final DMSO concentration is compatible with the assay and biological system.

If precipitation on dilution is observed: • Warm buffers to room temperature and add the DMSO stock last with vigorous mixing. • Consider including a low level of non-ionic surfactant (e.g., 0.01–0.02% Tween‑20) only after confirming no assay interference.

Green Alternatives

This item is a discrete small-molecule research tool, not a bulk solvent or commodity reagent, so conventional “green substitute” discussions are limited. Nevertheless, greener choices can be made around its use:

Greener handling choices (general guidance): • Stock solvent selection: If feasible, reduce reliance on high volumes of DMSO by exploring co‑solvent systems that include water or bio-based solvents (e.g., glycerol, propylene glycol) compatible with the assay. Validate effects on target and readout. • Minimize solvent waste: Prepare small aliquots at the minimum concentration that ensures complete dissolution to avoid repeated thaw/dilute cycles and disposal of expired solutions. • Micro-scale assays: Use miniaturized plate formats (384/1536‑well) to reduce per‑well solvent consumption. • Analytical methods: Favor LC conditions with water-rich mobile phases and short gradients; select less hazardous modifiers where possible (e.g., formic acid over TFA when MS sensitivity allows).

Trade-offs: • While greener co‑solvents reduce DMSO usage, they may compromise solubility or assay performance. Any substitution should be supported by recovery and control experiments. • Solid form and polymorph can alter dissolution behavior; green substitutions must be validated lot‑by‑lot.

Note: No item-specific “green certification” or solvent recommendations are provided in the Product Data; implement institutional green-chemistry policies as applicable.

Pharmaceutical Uses

No clinical or therapeutic claims are made for this product. For research use only.

Relevant non-clinical/formulation roles (general): • Analytical reference standard for method development and validation in bioanalytical LC–MS/MS (e.g., matrix calibration curves, stability studies). Purity and identity should be confirmed by CoA prior to qualification as a standard. • In vitro DMPK studies: substrate in microsomal/hepatocyte metabolism assays, plasma protein binding determinations, and transporter interaction screens to support discovery research. • Preformulation research: exploratory solubility, salt/screening, and polymorph studies to understand solid-state behavior for research-scale handling. No pharmacopeial monograph is indicated in the Product Data.

Note: Excipients, dosage forms, and clinical formulation details are out of scope and not provided. This material is supplied solely for laboratory research.

Physical Properties

Item-specific specifications: • Appearance: Not specified for this item; refer to CoA/Spec Sheet. • Melting point: Not specified for this item; refer to CoA/Spec Sheet. • Boiling point: Not applicable (decomposes before boiling under ambient pressure for most complex solids; item-specific data not provided). • Density: Not specified for this item; refer to CoA/Spec Sheet. • Solubility: Not specified for this item; refer to CoA/Spec Sheet. • LogP/logD: Not specified for this item; refer to CoA/Spec Sheet. • pKa: Not specified for this item; refer to CoA/Spec Sheet. • Refractive index/UV cutoff: Not applicable to solids; not specified.

General/literature guidance (non-specification): • As a drug-like, heteroaromatic kinase inhibitor, glesatinib is typically handled as a solid that is readily prepared as concentrated stock solutions in anhydrous DMSO for screening workflows. Actual solubility limits can vary by solid form and supplier; verify experimentally. • Hygroscopicity and polymorphism information are not provided for this item; if rigorous quantitative work (e.g., assay standardization) is planned, determine water content and confirm solid form by DSC/XRPD as needed.

Quality and Grades

• Grade: Moligand™ (as listed for this item). Moligand™ denotes a research-use screening compound suitable for ligand discovery, target validation, pathway interrogation, and reference/control purposes in biochemical and cellular assays.

What this typically implies (general, not a specification): • High chemical purity appropriate for small-molecule screening and assay development, with identity confirmed by orthogonal methods (e.g., NMR/HRMS/LC). Exact purity and analytical results are not specified for this item; refer to CoA/Spec Sheet. • No stabilizers or excipients are indicated in the Product Data; if formulation aids are present they will be listed on the CoA. • Batch-specific attributes such as water content, residual solvents, counter‑ion/solid form, and chromatographic purity can impact assay outcomes; consult the supplied CoA for these details.

Why grade matters: • Screening/assay grade materials help minimize confounders (unknown impurities/UV background) in enzymology, binding, and cell-based readouts. • For orthogonal readouts (e.g., biochemical vs. phenotypic), parallel testing of independently sourced batches is recommended to rule out batch‑specific artifacts.

Recommendations: • Document lot number in all data packages. • If LC/MS traceables or impurity profiles are critical, request the latest CoA and any available spectral data from technical support.

Reaction and Applications

This product is positioned as a research screening compound rather than a synthetic reagent. Accordingly, its primary applications are in chemical biology and assay development (general/literature), not as a stoichiometric reagent.

Representative research applications (non-exhaustive): • Target/pathway interrogation: Use as a small-molecule tool to probe MET/AXL signaling cascades in biochemical kinase assays, cellular phosphorylation readouts, and pathway mapping (literature). Choose appropriate positive/negative controls to contextualize results. • Reference standard: Analytical standard in LC/MS bioanalysis for exposure/PK studies and metabolism profiling; verify purity and solid form to ensure robust calibration. • Phenotypic screening: Employ as a characterized control to benchmark phenotypic responses attributable to MET-axis modulation. Combine with orthogonal genetic tools (e.g., siRNA/CRISPR) to support mechanism assignment. • Selectivity profiling: Incorporate into broad kinome panels to quantify off-target interactions and to build structure–activity relationships against related RTKs (literature practice).

Practical tips: • Prepare concentrated DMSO stock (e.g., 10–20 mM as a starting point; confirm solubility) and store in aliquots at −20°C to minimize freeze–thaw. • During aqueous dilution, add the DMSO stock last, with vortexing, and keep final DMSO ≤0.1–0.5% v/v for sensitive cell assays; determine tolerance per assay. • Confirm target engagement with orthogonal assays (e.g., biochemical IC50 vs. cellular pMET reduction) to control for permeability/efflux effects.

Reaction Conditions

As a finished small-molecule tool compound, glesatinib is not typically deployed as a reagent in chemical transformations; thus no synthetic reaction conditions apply to this item.

Assay preparation conditions (general/literature guidance): • Stock solutions: Prepare in anhydrous DMSO at a suitable concentration (e.g., 10–20 mM as a starting point; confirm solubility). Vortex thoroughly and, if needed, sonicate briefly to aid dissolution. • Working solutions: Dilute DMSO stocks into assay buffers to the desired final concentration, keeping final DMSO to the minimum tolerated by the system (commonly ≤0.1–0.5% v/v for sensitive cellular assays; up to ~1% v/v for many biochemical assays). Add DMSO stock last with mixing to minimize precipitation. • Temperature: Equilibrate solutions to room temperature before use to reduce solubility-induced precipitation. Avoid prolonged heating. • Light/moisture sensitivity: Protect from prolonged light and moisture during solution handling and storage. • Stability: Without item-specific stability data, adopt a conservative practice—use freshly prepared working solutions and limit repeated freeze–thaw cycles by aliquoting stocks.

Expected outcomes: Potency/readouts are assay-dependent. Establish standard curves and include vehicle controls to quantify any solvent-related baseline shifts.

Safety and Handling

Authoritative safety data are provided in the SDS; the following is general laboratory guidance.

GHS/label information (item-specific): • Signal word: Not specified for this item; refer to SDS. • Hazard statements (H-): Not specified for this item; refer to SDS. • Pictograms/GHS classification: Not specified for this item; refer to SDS.

Handling & PPE (general best practice): • Handle in a chemical fume hood; avoid inhalation of dust and contact with skin/eyes. • Wear lab coat, safety glasses, and chemical-resistant gloves (e.g., nitrile). Change gloves regularly during weighing and solution prep. • Avoid generating aerosols; use antistatic spatulas for fine powders.

Storage & incompatibilities: • Storage: Store at −20°C (per Product Data). Protect from moisture and prolonged light exposure. Keep container tightly closed. • Incompatibilities: Strong oxidizers and reducing agents may be incompatible with polyheteroaromatic organics; segregate from reactive chemicals. Avoid strong acids/bases during storage.

First-aid overview: • Skin/eye contact: Rinse with water for ≥15 min; remove contaminated clothing; seek medical attention as needed. • Inhalation: Move to fresh air; seek medical attention if symptoms occur. • Ingestion: Rinse mouth; do not induce vomiting; seek medical attention.

Waste & decontamination: • Collect solids/solutions as hazardous organic waste. Deactivate/neutralize only if a validated procedure exists. Decontaminate surfaces with appropriate organic solvent followed by detergent wash.

Solvent Selection

Item-specific solubility is not provided; the guidance below reflects common practice for kinase inhibitors (general/literature) and should be verified experimentally.

• Primary stock solvent: Anhydrous DMSO is the standard choice for small-molecule inhibitor stocks due to wide solubilizing power and assay compatibility at ≤0.1–1% v/v final. • Alternative co‑solvent systems: DMSO:water (with 0.5–2% v/v DMSO final), DMSO:PEG400, or DMSO:ethanol:water mixtures can improve solubility and reduce precipitation on dilution. Add solvent to compound first, then slowly back‑dilute into buffer with vigorous mixing. • Aqueous buffers: Direct dissolution into purely aqueous media is often limited for lipophilic kinase inhibitors. Use surfactant-containing buffers (e.g., 0.01–0.05% Tween‑20) only if validated not to interfere with assays. • Volatile solvents: For preparative purposes (e.g., thin film formation before reconstitution), use acetonitrile or methanol to wet the solid, then remove solvent and reconstitute in DMSO. Ensure complete drying to avoid unknown cosolvent effects. • Filtration: If particulate persists, filter DMSO stocks through PTFE (not nylon) syringe filters to avoid adsorption/interaction.

Comparison (general): • DMSO: highest solvency, widely compatible; potential enzyme inhibition at high %. • DMF/NMP: strong solvency but greater toxicity; typically avoided in biological assays. • Ethanol/MeOH: greener, but limited capacity for highly lipophilic scaffolds.

Storage and Reconstitution

Item-specific conditions: • Storage temperature: Store at −20°C (per Product Data). Shipments are sent in an ice chest with ice pads to maintain low temperature during transit. • Appearance and stabilizers: Not specified for this item; refer to CoA/Spec Sheet.

General guidance for reconstitution and handling: • Reconstitution: Dissolve the solid in anhydrous DMSO to prepare a concentrated stock solution. Start with 10–20 mM as a practical range, then adjust based on observed solubility (not specified for this item). • Aliquoting: Dispense single-use aliquots in amber vials or low-bind microtubes to avoid repeated freeze–thaw and adsorption losses. • Freeze–thaw: Minimize cycles. Thaw at room temperature, mix gently, and promptly return unused aliquots to −20°C. • Light/moisture protection: Keep containers tightly closed; purge headspace with inert gas if long-term storage is planned. Protect from prolonged light exposure. • Working solutions: Prepare fresh in the desired assay buffer immediately before use. If short-term storage is necessary, keep at 2–8°C and use within the same day unless stability has been empirically verified.

Documentation: • Record lot number, preparation date, stock concentration, and solvent composition on each aliquot. Consult the CoA/SDS for any additional, lot-specific storage or handling notes.

Research use only: Not for human or veterinary use.

Structure and Identity

• Product name: Glesatinib (literature synonym: MGCD265) • CAS: 936694-12-1 • InChIKey: 444680 (truncated in Product Data; full key not specified here) • SMILES: Not specified for this item; refer to CoA/Spec Sheet. • Molecular formula: Not specified for this item; refer to CoA/Spec Sheet. • Molecular weight: Not specified for this item; refer to CoA/Spec Sheet.

Structural features (general, literature): • Glesatinib is a small-molecule kinase inhibitor scaffold reported to target the MET/hepatocyte growth factor receptor (HGFR) pathway, with additional activity on AXL and related receptor tyrosine kinases (literature). It contains multiple heteroatoms and heteroaromatic features typical of ATP-competitive kinase inhibitors; exact functional group composition should be verified from primary structural references. • 2D description (literature, qualitative): polyheteroaromatic core with pendant aryl substituent(s) and donor–acceptor motifs designed to engage the kinase hinge region and solvent front. Precise ring count and substitution pattern are not specified here; consult the primary structure in authoritative databases before structural analyses.

Synthetic Utility

Glesatinib is an end-stage, structurally complex small molecule intended as a research tool compound. It is not typically used as a building block or reagent in routine organic synthesis.

Potential uses in synthesis/analysis (general): • Positive control/benchmark: Employed as a comparator in SAR campaigns targeting MET/AXL, helping to contextualize potency and selectivity of new analogs under identical assay conditions. • Degraders/PROTAC research: May serve as the target-binding “warhead” in bifunctional degrader exploration (literature concept). This requires bespoke linker installation strategies based on a known solvent-exposed vector; consult the primary structural literature to identify tolerated attachment points. Item-specific vectors and conjugation chemistries are not provided here. • Stability studies: Can be used as a probe for oxidative, photolytic, and hydrolytic stress during method validation, informing analytical method robustness.

Limitations: • Lacks obvious functional handles for straightforward diversification without prior route/scaffold knowledge. Any semisynthesis should be planned with full structural disclosure from primary sources. • No item-specific reactivity data are provided in the Product Data.

Target Specificity

Item-specific target specificity data are not provided in the Product Data for SKU G610571.

General/literature context (for background only; verify with primary sources): • Described as an ATP-competitive inhibitor of the MET receptor tyrosine kinase, with reported activity on AXL and selected related kinases depending on assay. Exact potency, selectivity panels, and off-target profiles vary with methodology and are not specified for this item.

For experimental planning, consult: • The item’s CoA (if available) for any vendor-supplied characterization. • Peer-reviewed kinase profiling datasets for glesatinib for study-specific target assignments.